Dr. Daniel R. Saltzstein, MD
Urology (Urology Physician)
- Medicare participating
At a glance
- Medical school
- University of Texas Medical School at San Antonio (1986)
- Years since graduation
- 40
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 1,143
Licensed in Texas since 1987, according to the Texas Medical Board. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1986Medical school: University of Texas Medical School at San Antonio
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Urology Physician primary
TX license H2005 (first issued 1987; active) -
Surgery Physician
TX license H2005 (first issued 1987; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Baptist Medical Center San Antonio, TX
- Methodist Hospital Stone Oak San Antonio, TX
Medical groups
- Urology PArtners of North Texas, PLLC (92 clinicians)
- Urology San Antonio P A (42 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 1,143
- Services billed
- 15,437
- Patients’ average age
- 76
| Service | Times | Patients |
|---|---|---|
| Injection, denosumab, 1 mg | 10,320 | 44 |
| Detection test by nucleic acid for organism, amplified probe technique | 1,608 | 112 |
| Manual urinalysis test with examination using microscope, automated | 1,260 | 827 |
| Established patient office or other outpatient visit, 30-39 minutes | 1,062 | 661 |
| Ultrasound measurement of bladder capacity after voiding | 900 | 678 |
| Psa (prostate specific antigen) measurement, total | 864 | 592 |
| Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month | 787 | 171 |
| Testosterone (hormone) level, total | 501 | 260 |
| Established patient office or other outpatient visit, 20-29 minutes | 290 | 267 |
| Blood test, basic group of blood chemicals (calcium, total) | 198 | 120 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Tamsulosin Hcl Other prescribers in San Antonio, TX | 1,136 |
| Finasteride Other prescribers in San Antonio, TX | 818 |
| Orgovyx (relugolix) | 644 |
| Erleada (apalutamide) | 275 |
| Myrbetriq (mirabegron) Other prescribers in San Antonio, TX | 233 |
| Abiraterone Acetate | 206 |
| Alfuzosin Hcl Er (alfuzosin hcl) Other prescribers in San Antonio, TX | 204 |
| Prednisone Other prescribers in San Antonio, TX | 191 |
| Xtandi (enzalutamide) | 144 |
| Nitrofurantoin (nitrofurantoin macrocrystal) Other prescribers in San Antonio, TX | 127 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 20 companies reported 91 payments worth $54,336 in total to this clinician.
| Janssen Biotech, Inc. | $14,054 |
|---|---|
| Pfizer Inc. | $7,018 |
| Astellas Pharma US Inc | $6,393 |
| Bayer HealthCare Pharmaceuticals Inc. | $6,355 |
| Novartis Pharmaceuticals Corporation | $5,365 |
| Telix Pharmaceuticals | $4,838 |
| Sumitomo Pharma America, Inc. | $3,852 |
| Ferring Pharmaceuticals Inc. | $2,415 |
| Consulting Fee | $27,329 |
|---|---|
| Compensation for services other than consulting (speaking, faculty) | $19,679 |
| Travel and Lodging | $2,904 |
| Food and Beverage | $2,211 |
| Honoraria | $2,188 |
| Education | $25.70 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Astellas Pharma US Inc Jun 20, 2025 | Consulting Fee Padcev · Oncology | $6,360 |
| Bayer HealthCare Pharmaceuticals Inc. Dec 12, 2025 | Compensation for services other than consulting (speaking, faculty) Nubeqa · Oncology | $4,998 |
| Janssen Biotech, Inc. Jun 19, 2025 | Compensation for services other than consulting (speaking, faculty) RYBREVANT; CARVYKTI · Oncology | $4,163 |
| Janssen Biotech, Inc. Mar 18, 2025 | Compensation for services other than consulting (speaking, faculty) RYBREVANT; CARVYKTI · Oncology | $4,163 |
| Sumitomo Pharma America, Inc. May 15, 2025 | Compensation for services other than consulting (speaking, faculty) ORGOVYX · PROSTATE CANCER | $3,575 |
| Janssen Biotech, Inc. May 9, 2025 | Consulting Fee | $3,191 |
| Novartis Pharmaceuticals Corporation Jul 8, 2025 | Consulting Fee | $2,700 |
| Ferring Pharmaceuticals Inc. Apr 9, 2025 | Consulting Fee ADSTILADRIN · ONCOLOGY | $2,415 |
| Urogen Pharma, Inc. Nov 14, 2025 | Honoraria ZUSDURI · LG-IR-NMIBC | $2,188 |
| Novartis Pharmaceuticals Corporation Jul 17, 2025 | Consulting Fee | $2,025 |
All 32 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Bayer HealthCare Pharmaceuticals Inc. Dec 12, 2025 | Compensation for services other than consulting (speaking, faculty) Nubeqa · Oncology | $4,998 |
| Novartis Pharmaceuticals Corporation Dec 5, 2025 | Travel and Lodging PLUVICTO · Oncology · travel to Denver, CO · in-kind | $419 |
| Pfizer Inc. Nov 17, 2025 | Consulting Fee | $500 |
| Urogen Pharma, Inc. Nov 14, 2025 | Honoraria ZUSDURI · LG-IR-NMIBC | $2,188 |
| Janssen Biotech, Inc. Oct 3, 2025 | Consulting Fee ERLEADA · Oncology | $1,388 |
| Merck Sharp & Dohme LLC Aug 23, 2025 | Education LYNPARZA · ONCOLOGY · in-kind | $25.70 |
| Pfizer Inc. Jul 24, 2025 | Consulting Fee | $1,500 |
| Novartis Pharmaceuticals Corporation Jul 17, 2025 | Consulting Fee | $2,025 |
| Novartis Pharmaceuticals Corporation Jul 8, 2025 | Consulting Fee | $2,700 |
| Bayer HealthCare Pharmaceuticals Inc. Jul 3, 2025 | Compensation for services other than consulting (speaking, faculty) Nubeqa · Oncology | $1,176 |
| Astellas Pharma US Inc Jun 20, 2025 | Consulting Fee Padcev · Oncology | $6,360 |
| Janssen Biotech, Inc. Jun 19, 2025 | Compensation for services other than consulting (speaking, faculty) RYBREVANT; CARVYKTI · Oncology | $4,163 |
| Janssen Biotech, Inc. May 24, 2025 | Compensation for services other than consulting (speaking, faculty) RYBREVANT; CARVYKTI · Oncology | $555 |
| Pfizer Inc. May 20, 2025 | Consulting Fee TALZENNA · ONCOLOGY | $1,500 |
| Sumitomo Pharma America, Inc. May 15, 2025 | Compensation for services other than consulting (speaking, faculty) ORGOVYX · PROSTATE CANCER | $3,575 |
| Pfizer Inc. May 13, 2025 | Consulting Fee | $1,500 |
| Pfizer Inc. May 13, 2025 | Consulting Fee | $1,000 |
| Sumitomo Pharma America, Inc. May 12, 2025 | Travel and Lodging ORGOVYX · PROSTATE CANCER · travel to AUSTIN, TX | $101 |
| Sumitomo Pharma America, Inc. May 12, 2025 | Travel and Lodging ORGOVYX · PROSTATE CANCER · travel to AUSTIN, TX | $23.00 |
| Janssen Biotech, Inc. May 9, 2025 | Consulting Fee | $3,191 |
| Pfizer Inc. Apr 26, 2025 | Travel and Lodging LORBRENA · ONCOLOGY · travel to Las Vegas, NV · in-kind | $621 |
| Pfizer Inc. Apr 26, 2025 | Travel and Lodging LORBRENA · ONCOLOGY · travel to Las Vegas, NV · in-kind | $305 |
| Telix Pharmaceuticals Apr 24, 2025 | Consulting Fee ILLUCCIX · PROSTATE CANCER DIAGNOSIS | $2,000 |
| Telix Pharmaceuticals Apr 24, 2025 | Consulting Fee ILLUCCIX · PROSTATE CANCER DIAGNOSIS | $1,250 |
| Janssen Biotech, Inc. Apr 23, 2025 | Travel and Lodging travel to DALLAS, TX · in-kind | $136 |
| Ferring Pharmaceuticals Inc. Apr 9, 2025 | Consulting Fee ADSTILADRIN · ONCOLOGY | $2,415 |
| Janssen Biotech, Inc. Apr 4, 2025 | Travel and Lodging RYBREVANT; CARVYKTI · Oncology · travel to Southlake, TX | $120 |
| Janssen Biotech, Inc. Mar 18, 2025 | Compensation for services other than consulting (speaking, faculty) RYBREVANT; CARVYKTI · Oncology | $4,163 |
| Dendreon Pharmaceuticals LLC Mar 10, 2025 | Compensation for services other than consulting (speaking, faculty) PROVENGE · CELLULAR BIOLOGIC TREATMENT FOR PROSTATE CANCER | $1,050 |
| Telix Pharmaceuticals Mar 8, 2025 | Travel and Lodging ILLUCCIX · PROSTATE CANCER DIAGNOSIS · travel to NASHVILLE, TN | $612 |
| Telix Pharmaceuticals Mar 7, 2025 | Travel and Lodging ILLUCCIX · PROSTATE CANCER DIAGNOSIS · travel to NASHVILLE, TN | $410 |
| Janssen Biotech, Inc. Mar 4, 2025 | Travel and Lodging travel to DALLAS, TX · in-kind | $157 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 6 industry-funded studies in 2025, from 5 companies. The companies reported $237,361 in research payments for these studies, mostly to the institutions running them.
- Intrapatient Comparison of Urinary Radioactivity Following Piflufolastat (18F) and Flotufolastat (18F) PET in Men With Low PSA Biochemical Recurrence of Prostate Cancer Following Radical Prostatectomy
Blue Earth Diagnostics · Completed · NCT06604442 - A Study of Tazemetostat With Enzalutamide or Abiraterone/Prednisone in Participants With Advanced Prostate Cancer
Epizyme, Inc. · Terminated · NCT04179864 - A Phase III, Open-label, Multi-center, Randomized Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive Metastatic Castration Resistant Prostate Cancer
Novartis Pharmaceuticals Corporation - A Phase II, Open-label, Multi-Center, Randomized Study Comparing the Combination of Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) and Androgen Receptor Pathway Inhibitor (ARPI) vs. Lutetium (177Lu) Vipivotide Tetrax…
Novartis Pharmaceuticals Corporation - Metastatic Castrate-Resistant Prostate Cancer Subjects Treated With PROVENGE® + One Infusion of Sipuleucel-T
Dendreon Pharmaceuticals LLC · Recruiting · NCT06134232 - BL007 - a rollover study to follow the long-term outcomes of patients from study UT001 (formerly tc-UT-03) and study tc-BC-12
Urogen Pharma, Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.